Answers are grounded in this paper and cite their sources.
Case-control study evaluates IL-10 and IL-12 as early biomarkers for type 2 diabetes, indicating their diagnostic potential.
Background: Type 2 diabetes mellitus (T2DM) is increasingly recognized as a complex metabolic disorder associated with immune dysregulation and chronic low-grade inflammation Objectives: This study aimed to quantify serum levels of (IL-10) and (IL-12) in patients with (T2DM) and to explore their potential role as early diagnostic biomarkers in comparison with healthy controls. Methods: A case–control study be situated showed including 120 participants: 80 patients with T2DM and 40 healthy controls. Serum concentrations of IL-10 and IL-12 were quantified using ELISA. Hematological and biochemical parameters were assessed using standard automated methods. Statistical analyses included independent t-tests, correlation analysis, and receiver operating characteristic (ROC) curve analysis to evaluate diagnostic performance. Results: Serum IL‑10 levels remained significantly lower in patients with T2DM related with controls (15.59 ± 5.79 vs. 20.53 ± 9.64 pg/mL, p = 0.01). Similarly, IL‑12 concentrations were significantly reduced in the patient group (15.31 ± 6.22 vs. 20.59 ± 8.43 pg/mL, p = 0.03). Patients also exhibited significantly higher HbA1c and WBC levels (p < 0.001). ROC analysis demonstrated that mutually IL‑10 and IL‑12 showed moderate diagnostic accuracy for distinguishing patients from controls. Conclusion: Reduced serum levels of IL‑10 and IL‑12 reflect early immune dysregulation in T2DM and support their potential use as complementary diagnostic biomarkers alongside conventional metabolic indicators.
No takes yet. Share an insight, caveat, or question.
Shail et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: